Detalles de la búsqueda
1.
Editorial for "Quantification of Prostate Cancer Metabolism Using 3D Multiecho bSSFP and Hyperpolarized [1-13 C] Pyruvate: Metabolism Differs Between Tumors of the Same Gleason Grade".
J Magn Reson Imaging
; 57(6): 1876-1877, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36326566
2.
Improved positron emission tomography imaging of glioblastoma cancer using novel 68Ga-labeled peptides targeting the urokinase-type plasminogen activator receptor (uPAR).
Amino Acids
; 49(6): 1089-1100, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28316028
3.
Preclinical Study on GRPR-Targeted (68)Ga-Probes for PET Imaging of Prostate Cancer.
Bioconjug Chem
; 27(8): 1857-64, 2016 08 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-27399868
4.
Prospective Phase II Trial of [68Ga]Ga-NODAGA-E[c(RGDyK)]2 PET/CT Imaging of Integrin αvß3 for Prognostication in Patients with Neuroendocrine Neoplasms.
J Nucl Med
; 64(2): 252-259, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35981899
5.
An Investigation of Lesion Detection Accuracy for Artificial Intelligence-Based Denoising of Low-Dose 64Cu-DOTATATE PET Imaging in Patients with Neuroendocrine Neoplasms.
J Nucl Med
; 64(6): 951-959, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37169532
6.
Activity Dose Reduction in 64Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Impact on Image Quality and Lesion Detection Ability.
Mol Imaging Biol
; 24(4): 600-611, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35167028
7.
Prospective Phase II Trial of Prognostication by 68Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted Therapy.
J Nucl Med
; 63(9): 1371-1377, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35058319
8.
A convolutional neural network for total tumor segmentation in [64Cu]Cu-DOTATATE PET/CT of patients with neuroendocrine neoplasms.
EJNMMI Res
; 12(1): 30, 2022 May 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35633448
9.
A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors.
J Nucl Med
; 63(3): 376-383, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34215673
10.
First-in-Humans PET Imaging of Tissue Factor in Patients with Primary and Metastatic Cancers Using 18F-labeled Active-Site Inhibited Factor VII (18F-ASIS): Potential as Companion Diagnostic.
J Nucl Med
; 63(12): 1871-1879, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35589407
11.
Semiautomatic Tumor Delineation for Evaluation of 64Cu-DOTATATE PET/CT in Patients with Neuroendocrine Neoplasms: Prognostication Based on Lowest Lesion Uptake and Total Tumor Volume.
J Nucl Med
; 62(11): 1564-1570, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33637589
12.
Initial Experience with 64Cu-DOTATATE Digital PET of Patients with Neuroendocrine Neoplasms: Comparison with Analog PET.
Diagnostics (Basel)
; 11(2)2021 Feb 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-33669838
13.
64Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours After Injection.
J Nucl Med
; 62(1): 73-80, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32444370
14.
[68Ga]Ga-NODAGA-E[(cRGDyK)]2 Angiogenesis PET/MR in a Porcine Model of Chronic Myocardial Infarction.
Diagnostics (Basel)
; 11(10)2021 Sep 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-34679505
15.
64Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine Neoplasms.
J Nucl Med
; 61(10): 1491-1497, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32111685
16.
Falsk positiv lungeperfusionsdefekt på baggrund af pulmonalarteriemalformation.
Ugeskr Laeger
; 186(18)2024 Apr 29.
Artículo
en Da
| MEDLINE | ID: mdl-38704718
17.
Multimodality Hyperpolarized C-13 MRS/PET/Multiparametric MR Imaging for Detection and Image-Guided Biopsy of Prostate Cancer: First Experience in a Canine Prostate Cancer Model.
Mol Imaging Biol
; 21(5): 861-870, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30793241
18.
The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy.
Eur Urol Focus
; 4(3): 360-368, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28753827
19.
Temporal Trends in Clinical and Pathological Characteristics for Men Undergoing Radical Prostatectomy Between 1995 and 2013 at Rigshospitalet, Copenhagen, Denmark, and Stanford University Hospital, United States.
Clin Genitourin Cancer
; 2017 Sep 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28988695
Resultados
1 -
19
de 19
1
Próxima >
>>